The PROOF (Prevention of Organ Failure) Centre, a not-for-profit Centre of Excellence for Commercialisation and Research funded by the Government of Canada, has licensed the popular GVK BIO Online Clinical Biomarker Database (GOBIOM) to help evaluate the commercialisation potential of the PROOF Centre’s biomarkers for heart, lung and kidney disease.

"Heart, lung and kidney diseases are a tremendous cost to society in dollars and lives. Our mission at the PROOF Centre is to create new tools that will help alleviate this global burden," says Dr. Bruce McManus, Director of the PROOF Centre. "Integrating knowledge from GVK Biosciences’ biomarker database will be a significant advantage in helping us accelerate the transfer of these new tests into the clinic – ensuring patients will benefit faster."

The GOBIOM database is a comprehensive collection of all the clinically evaluated, exploratory and preclinical biomarkers associated with different therapeutic areas reported in global clinical trials, clinical and preclinical studies. GOBIOM contains information on 14,000 biomarkers comprising of biochemical, genomic, imaging, metabolite, cellular and physiological markers with multiple data points covering experimental, analytical, clinical and statistical data with their qualifications under different medical interventions. Over 100 different ethnicities are covered in the database. The unique data model links the biomarker to the drug, therapeutic area and target and allows users to query the database in multiple ways. The database also contains significant amount of toxicity and adverse events data.

Sreeni Devidas, Vice President, Sales and Marketing – Informatics, said "the GOBIOM database has received good response from the academia and industry. The license by the PROOF Centre of Excellence further validates the utility of the database. We look forward to working with the researchers at the PROOF Centre of Excellence and helping them in their scientific strategies."